On the stock market since 2004, it operates in the world of health and science. It has 3 employees. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The stock sits at $0.54. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 13/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 16/100.
On our five-subject report card, OGEN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OGEN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.